According to Corcept Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 83.5568. At the end of 2022 the company had a P/E ratio of 21.4.
Year | P/E ratio | Change |
---|---|---|
2022 | 21.4 | 4.74% |
2021 | 20.4 | -28.21% |
2020 | 28.4 | 95.05% |
2019 | 14.6 | -29.07% |
2018 | 20.6 | 28.6% |
2017 | 16.0 | -84.63% |
2016 | 104 | -246.14% |
2015 | -71.1 | 635.14% |
2014 | -9.68 | 38.68% |
2013 | -6.98 | 100.08% |
2012 | -3.49 | -59.21% |
2011 | -8.55 | -13.61% |
2010 | -9.90 | 35.29% |
2009 | -7.32 | 208.41% |
2008 | -2.37 | -73.9% |
2007 | -9.09 | 705.38% |
2006 | -1.13 | -72.79% |
2005 | -4.15 | -40.94% |
2004 | -7.02 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.